COVID-19出院后3个月与1年胸部CT肺部异常随访
前瞻性队列纳入80例COVID-19出院患者,3个月随访时56%存在CT异常,以磨玻璃影和条带影为主,明确纤维化征象仅12%;1年随访时多数异常进一步改善。急性期炎症指标升高、住院时间长、高龄及有创通气与3个月CT异常相关。
要点
- COVID-19出院3个月CT异常常见,磨玻璃影48%、条带影37%,明确纤维化仅12%。
- 3个月CT异常与急性期CRP、纤维蛋白原、尿素、肌酐升高及有创通气相关。
- 3个月CT异常者1年随访81%进一步改善,提示多数为可逆性改变。
核心结论
- COVID-19出院3个月CT异常常见,但明确纤维化征象仅少数。
- 急性期病情越重,3个月CT异常风险越高。
- 1年随访多数患者影像学进一步改善。
研究设计与样本
- PHENOTYPE观察性前瞻队列研究,纳入2020年3月至6月出院的80例成人COVID-19患者。
- 出院后3个月和1年系统评估症状、功能受损及胸部CT,肺功能仅限CT异常或持续呼吸困难者。
- CT随访中位105天(IQR 95–141天),异常者复查中位364天(范围360–366天)。
- 采用Bonferroni校正,临床试验注册号NCT04459351。
关键影像表现/征象
- 3个月CT异常41/73例(56%),以磨玻璃影35/73(48%)和条带影27/73(37%)为主。
- 明确纤维化征象(体积缩小和/或牵拉性支气管扩张)9/73例(12%)。
临床应用与阅片要点
- COVID-19出院3个月CT见磨玻璃影和条带影常见,报告可描述为残留改变而非明确纤维化。
- 仅少数出现体积缩小或牵拉性支气管扩张等明确纤维化征象,报告需谨慎使用纤维化术语。
- 急性期CRP、纤维蛋白原、尿素、肌酐升高、住院时间长、高龄及有创通气者,3个月CT异常风险较高。
- 3个月CT异常者多数1年随访进一步改善,随访报告可对比前片描述变化趋势。
局限性
- 肺功能仅限CT异常或持续呼吸困难者,无全院系统肺功能数据。
- 1年复查时间窗窄(360–366天),未报告组织学对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Data on the long-term pulmonary sequelae in COVID-19 are lacking. Purpose To assess symptoms, functional impairment, and residual pulmonary abnormalities on serial chest CT scans in COVID-19 survivors discharged from hospital at up to 1-year follow-up. Materials and Methods Adult patients with COVID-19 discharged between March 2020 and June 2020 were prospectively evaluated at 3 months and 1 year through systematic assessment of symptoms, functional impairment, and thoracic CT scans as part of the PHENOTYPE study, an observational cohort study in COVID-19 survivors. Lung function testing was limited to participants with CT abnormalities and/or persistent breathlessness. Bonferroni correction was used. Results Eighty participants (mean age, 59 years ± 13 [SD]; 53 men) were assessed. At outpatient review, persistent breathlessness was reported in 37 of the 80 participants (46%) and cough was reported in 17 (21%). CT scans in 73 participants after discharge (median, 105 days; IQR, 95-141 days) revealed persistent abnormalities in 41 participants (56%), with ground-glass opacification (35 of 73 participants [48%]) and bands (27 of 73 participants [37%]) predominating. Unequivocal signs indicative of established fibrosis (ie, volume loss and/or traction bronchiectasis) were present in nine of 73 participants (12%). Higher admission serum C-reactive protein (in milligrams per liter), fibrinogen (in grams per deciliter), urea (millimoles per liter), and creatinine (micromoles per liter) levels; longer hospital stay (in days); older age (in years); and requirement for invasive ventilation were associated with CT abnormalities at 3-month follow-up. Thirty-two of 41 participants (78%) with abnormal findings at 3-month follow-up CT underwent repeat imaging at a median of 364 days (range, 360-366 days), with 26 (81%) showing further radiologic improvement (median, 18%; IQR, 10%-40%). Conclusion CT abnormalities were common at 3 months after COVID-19 but with signs of fibrosis in a minority. More severe acute disease was linked with CT abnormalities at 3 months. However, radiologic improvement was seen in the majority at 1-year follow-up. ClinicalTrials.gov identifier: NCT04459351. © RSNA, 2022 Online supplemental material is available for this article.
引用
- Vijayakumar B, Tonkin J, Devaraj A, et al. CT Lung Abnormalities after COVID-19 at 3 Months and 1 Year after Hospital Discharge. Radiology. 2021. PMID: 34609195. doi:10.1148/radiol.2021211746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。